A designer hyper interleukin 11 (H11) is a biologically active cytokine
© Dams-Kozlowska et al; licensee BioMed Central Ltd. 2012
Received: 6 December 2011
Accepted: 21 March 2012
Published: 21 March 2012
Interleukin 11 (IL-11) is a pleiotropic cytokine with anti-apoptotic, anti-inflammatory and hematopoietic potential. The IL-11 activity is determined by the expression of the IL-11R receptor alpha (IL-11Rα) and the signal transducing subunit β (gp130) on the cell membrane. A recombinant soluble form of the IL-11Rα (sIL-11Rα) in combination with IL-11 acts as an agonist on cells expressing the gp130 molecule. We constructed a designer cytokine Hyper IL-11 (H11), which is exclusively composed of naturally existing components. It contains the full length sIL-11Rα connected with the mature IL-11 protein using their natural sequences only. Such a construct has two major advantages: (i) its components are as close as possible to the natural forms of both proteins and (ii) it lacks an artificial linker what should avoid induction of antibody production.
The H11 construct was generated, the protein was produced in a baculovirus expression system and was then purified by using ion exchange chromatography. The H11 protein displayed activity in three independent bioassays, (i) it induced acute phase proteins production in HepG2 cells expressing IL-11, IL-11Rα and gp130, (ii) it stimulated the proliferation of B9 cells (cells expressing IL-11Rα and gp130) and (iii) proliferation of Baf/3-gp130 cells (cells not expressing IL-11 and IL-11Rα but gp130). Moreover, the preliminary data indicated that H11 was functionally distinct from Hyper-IL-6, a molecule which utilizes the same homodimer of signal transducing receptor (gp130).
The biologically active H11 may be potentially useful for treatment of thrombocytopenia, infertility, multiple sclerosis, cardiovascular diseases or inflammatory disorders.
IL-11 is a pleiotropic cytokine, which exhibits multiple biological activities which are determined by expression of IL-11Rα and gp130 on the cell membrane . Originally it was identified in 1990 as a molecule promoting growth of the IL-6-dependent mouse plasmacytoma cell line B9 . It has been demonstrated later, that IL-11 exhibits multiple effects not only on hematopoietic system, but it also acts on various cell types of the liver, gastrointestinal tract, lung, heart, central nervous system, bone, joint and immune system . IL-11 acts synergistically with other growth factors in the process of hematopotic cells differentiation including progenitor cells, and on megakaryocytopoiesis, thrombopoiesis, erythropoiesis and myelopoiesis . Moreover, IL-11 displays anti-melanoma activity when used as molecular adjuvant in the therapeutic whole cell melanoma vaccine formulation .
IL-11 together with IL-6, IL-27, Leukemia Inhibitory Factor (LIF), Oncostatin M (OSM), Ciliary Neurotrophic Factor (CNTF), Cardiotrophin 1 (CT-1), cardiotrophin-like cytokine (CLC) and neuropoietin (NP) belongs to the family of hemopoietic cytokines (named IL-6-type or gp130 cytokines), which share structural similarity and a common receptor subunit (gp130) [4, 5]. Some of the IL-6-type cytokines require a specific (unique) receptor complex, however, always one or two subunits of a common transmembrane transducer receptor gp130 is required. IL-6 and IL-11 engage a homodimer of gp130. Other IL-6-type cytokines like LIF, CT-1, CNTF, NP, CLC need LIF receptor (LIFR) and gp130. OSM binds first to gp130 and then with either LIFR or OSMR. IL-27 forms signaling complex with gp130 and WSX-1 (IL-27R). Moreover, some of the IL-6 type interleukins first bind to a specific receptor alpha and then engage signal transducer subunits . Cytokines utilizing gp130 molecule induce signaling via the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway and also the Mitogen-Activated Protein Kinase (MAPK) cascade .
Specifically, the IL-11 receptor complex is formed via three separate events. First, IL-11 binds with low affinity to membrane specific receptor α. Next, IL-11/IL-11Rα heterodimer binds with high affinity to receptor gp130 forming heterotrimer. At the last stage, the heterotrimers associate forming a hexameric complex that elicits the biological response. The stoichiometry of the high affinity IL-11 receptor complex has been determined in vitro as a hexamer consisting of two IL-11 molecules, two IL-11Rα chains and a homodimer of two gp130 molecules .
The gp130 protein was found on all human cell types so far studied, however the expression of other IL-6-type receptor subunits is limited. Cells that express the proper subunit will be sensitive to the respective cytokine. Moreover, soluble forms of the alpha receptors lacking the transmembrane and cytoplasmic domains were found . Soluble forms of cytokine receptors can be produced by limited proteolysis of the membrane-bound receptor or by translation of alternatively spliced mRNA . Cells that do not express receptor α can be sensitive to the complex of cytokine/soluble cytokine receptor α. Recombinant soluble IL-11Rα (sIL-11Rα) can bind IL-11 and then the comples attracts gp130 leading to signal transduction . The complex of IL-11/sIL-11Rα can activate cells bearing both IL-11Rα and gp130 subunits or gp130 only. The recombinant sIL-11Rα acts in vitro as IL-11 agonist, although antagonizing activity was also observed [10–12].
In order to increase and modify the potential bioactivity of some cytokines, the idea of linking of two soluble, naturally existing components was postulated. The fusion proteins are expected to be more stable and are needed at a lower effective dose. Examples derived from IL-6-type cytokines include fusion proteins consisting of different fragments of alpha receptors and their cognate cytokines like IL-6/sIL-6R (Hyper IL-6), IL-11/sIL-11Rα (IL-11/R-FP) and CNTF/sCNTFR (Hyper-CNTF) [13–15]. Here, we constructed a novel cytokine Hyper IL-11 (H11), which is composed of naturally existing components only. It contains the full length soluble IL-11Rα connected with IL-11. Since the natural sequence of C-terminus of IL-11Rα and N-terminus of IL-11 were used, we could refrain from using artificial linker sequences for the connection of both components.
Construction of H11
Production and purification of H11 protein
Activity of H11
The purified recombinant H11 was tested for biological activity in three different in vitro bio-assays: human hepatoma cell line HepG2-assay, murine B9 (hybridoma cell line) bio-assay, and murine Ba/F3-gp130 bio-assay.
Signal transduction mediated by H11
Differentiation study of hematopoietic Lin-CD34+ cells
Concept of the construction of recombinant fusion proteins derived from IL-6 cytokines is not new. It is based on the strategy of linking the cytokines and their cognate soluble α receptor. The α receptors posses extracellular N-terminal domain and one transmembrane domain (with exception of CNTFR, which is linked to the membrane by a lipid anchor). Structurally, following predicted regions can be distinguished: (i) signal peptide, (ii) Ig-like region-D1 domain, (iii) cytokine binding homology domain (CHD) consisting of two fibronectin-type-III-like domains (FNIII) termed D2 and D3., (iv) receptor pre-membrane region, (v) transmembrane, and (vi) cytoplasmic regions. The designed fusion proteins contained different structural parts of its α receptor. Hyper-IL-6 consisted of D2 and D3 domain of IL-6R α chain (AA residues 113-323) connected to IL-6 (AA 29-212) via artificial polypeptide linker . Hyper-IL-6 is a fully active fusion protein, which mediates response at 10-1000-fold lower doses as compared to the combination of soluble IL-6 and sIL-6R molecules . In analogy, another superagonist was designed named IL-11/R-FP . IL-11/R-FP was created by covalently linking D2 and D3 domains of IL-11Rα (position L/109-G/318) with IL-11 (position P/29-L/199) using a 21 amino acid linker. It demonstrated 50 fold higher activity in vitro than the combination of IL-11 and sIL-11Rα. However, such construct was also composed of interleukin and a truncated segment of the alpha receptor (as Hyper IL-6), so it lacked naturally existing parts of the used receptor. Moreover, the used artificial linker is not a naturally occurring sequence, thus it might demonstrate potential immunogenicity when used for treatment of human patient. Hyper-CNTF was another example of a superagonist composed of sCNTFR (AA 1-346) and CNTF (AA 1-186) . It differed from the previous IL-6 type fusion proteins (Hyper IL-6 and IL-11/R-FP), since it included the Ig domain of sCNTFR. Although the D3 domain of the interleukin alpha receptor is mainly involved in ligand binding  and its D2-D3 part is sufficient to induce biological activity in vitro [13, 14], the role of the Ig-like domain and the membrane proximal region can not be disregarded. It was shown that the Ig-domain of the IL-6R is important for intracellular transport of IL-6R through the secretory pathway . It can also be involved in interdomain stabilization or induction of conformational change of the ligand. Moreover, for fusion of CNTFR and CNTF the C-terminal end of CNTFR and N-terminal end of CNTF was used, which were linked by one additional glycine residue . A synthetic polypeptide linker was not applied in order to minimize potential immunogenicity. The mentioned terminal ends are presumably flexible and sufficient to allow access of cytokine to its receptor alpha binding sites. Indeed, Hyper-CNTF was biologically active . In terms of construction, our Hyper-IL-11 (H11) resembles mostly Hyper-CNTF. It is composed of full length of soluble IL-11 receptor and IL-11, and both elements are connected by natural existing parts of receptor and interleukin. It differs from Hyper-CNTF, since the additional glycine residue was not incorporated in the fusion and also the flexible termini of sIL-11Rα and IL-11 generated a longer linker. For construction of Hyper-IL-6, a 29 AA linker was used, while for IL-11/R-FP 31 AA and Hyper-CNTF 31 AA were applied [13–15]. With our hyper-molecule, a 67 AA linker was generated, since the pre-membrane region of IL-11Rα (51 amino acids) together with 16 N-terminal residues of IL-11 is not helical and presumably flexible. It should enable the proper positioning of the fusion molecule. In general, the construction of our hyper-cytokine has two major advantages: (i) its components are as close as possible to the natural forms of both proteins and (ii) omitting of the artificial linker should prevent possible immunogenicity and other side effects due to the non-natural recombinant agent.
In the case of Hyper-IL-6, the high potency of the designer cytokine is based on the fact that the affinity of IL-6 to the IL-6R is in the range of 1 nM whereas the affinity of the complex of IL-6 and IL-6R is 6R is around 10-15 pM, which is about 100 times higher. If the affinities between IL-11 and the two receptor subunits are in the same range, this would explain the high biologic activity of the H11 protein.
Although sIL-11Rα was not found in human body fluids so far, its existence has been postulated due to identification of a transcript potentially encoding sIL-11Rα . The recombinant sIL-11Rα in vitro acts as IL-11 agonist [10–12]. In addition, the sIL-11Rα not only potentiated effects of the IL-11 on cells that are normally responsive to IL-11, but also in the presence of IL-11 it mediated a signal transduction in cells expressing gp130 molecules only [10, 12]. However, the concentration of IL-11 required to mediate a biological response using sIL-11Rα had to be 10- 20-fold higher than using membrane receptor . Expression of IL-11Rα is limited to certain cell types, while gp130 is present on all cells of the body. Thus, the use of the sIL-11Rα significantly widens the range of IL-11 bioactivity. Furthermore, sIL-11Rα can act as an IL-11 antagonist when tested on cells expressing the membrane IL-11Rα and gp130 . The antagonism probably resulted from the competition between soluble and cellular IL-11Rα for IL-11 and/or was depended on the number of gp130 molecules . Our Hyper-IL-11 acts as agonist when tested in HepG2-assay, in B9 and in Ba/F3gp130 bio-assays. Since sIL-11Rα presumably is already occupied by IL-11, it does not compete with endogenous IL-11 or membrane bound IL-11Rα, which explains its agonistic activity. The previously described molecule IL-11/R-FP also acted as agonist when tested in HepG2 and Ba/F3-gp130 assays . When Ba/F3-gp130 cells were stimulated with IL-11/R-FP, a concentration 130-140 pM was sufficient for half-maximum proliferation. Our H11 induced the half-maximum proliferation at the dose of approximately 800-900 pM. However, IL-11/R-FP was non purified and its calculated concentration could be misleading. According to Pflanz et al. the concentration of IL-11/R-FP in the yeast supernatant was calculated from the band intensities of IL-11/R-FP and serial dilutions of IL-11 preparation of a known concentration measured by a Lumi-Imager . Since the analyzed material was derived from not purified yeast supernatant, presumably the concentration was calculated after immunoblotting (it was not defined). Our experience indicated that antibodies anti IL-11 or IL-11Rα not necessarily recognize fusion molecule with the same affinity. When several ELISA systems were used to measure H11 concentration, different results were obtained (data not shown). The antigenic determinant at a fusion molecule may be hidden or partially hidden when compared with the epitope of parental components (IL-11 or IL-11Rα), what can explain the observed differences. In order to compare correctly the activity of both fusion proteins (H11 and IL-11/R-FP) the experiment should be conducted simultaneously using purified proteins, which concentration was calculated with the same method.
After binding to their cognate α receptor, cytokines IL-6 and IL-11 engage a homodimer of gp130 in order to elicit signal transduction. Since, both designer cytokines, H11 and Hyper-IL-6 compromise of cytokine and its cognate α receptor, they need the same receptor subunits for signal transduction. That is why H11 and Hyper-IL-6 may be functionally equivalent. According to our preliminary results H11 retains in part an IL-11Rα-specific activity that is directed by H11 interaction with gp130. In terms of hematopietic differentiation H11 increased expression of early erythroid antigen. IL-11 is well known to be involved in the expansion of megakaryiocyte progenitors, and megakariocytes derive from common megakaryocyte/erythrocyte progenitor . However, Hyper IL-6 did not exert the same effect. Contrary, it stimulated myelopoiesis, what is in agreement with previous data . Although, IL-6 and IL-11 share the common receptor subunit (gp130), they bind to the different sites on it [24, 25], what can influence on the specific response mediated by gp130 signaling. The proliferation of TF1 cells induced by IL-11 but not by IL-6 could be inhibited by a specific antibody anti gp130 (B-P4). On the other hand, using SK-N-MC cells, the same antibody could not block the phosphorylation of gp130 induced by IL-11 and by IL-6 . Moreover, PHA-activated T-cells responded to IL-6 by mobilization of a heterodimer STAT1/STAT3 and homodimer STAT1, while IL-11/sIL-11Rα by a STAT3 homodimer and STAT3/STAT1 heterodimer . These results indicated that although structurally cytokines share the same signal transducing unit, its activation may elicit different effects, like different global phosphorylation level, activation of different STAT molecules what may influence the final biological activity. Such difference may be critical to activation of distinct regulation processes depending on the cell origin. However, whether this kind of differences are responsible for diverse action of H11 and Hyper-IL-6 needs to be evaluated.
Since IL-11 is a pleiotropic cytokine of hematopoietic and anti-inflammatory properties, H11 may be potentially beneficial in the treatment of various diseases. IL-11 is the only agent approved by USA Food and Drug Administration (FDA) to prevent severe thrombocytopenia and reduce the need for platelet transfusion following myelosuppressive chemotherapy for non-myeloid malignancies. Accordingly, studies of H11 in similar models are required. Even if in vivo studies demonstrate unacceptable toxicity it does not exclude utility of H11 for ex vivo expansion of megakaryocyte precursor cells. Our preliminary in vitro studies have indicated great potential of H11 for megakaryocyte expansion (data not shown). Moreover, recent studies have shown that IL-11 regulated the autoimmune demyelination disease-multiple sclerosis (MS) . Due to its dual action: immunomodulatory and neuroprotective/regenerative, IL-11 may display a unique potential to treat MS. Loss of IL-11Rα expression was associated with severe symptoms of autoimmune encephalomyelitis (EAE) in the mouse model of MS. IL-11 treatment of mice with EAE gave partial, albeit statistically significant, therapeutic benefit. Another example of potential H11 utility is to treat infertility. Mice lacking IL-11Rα are infertile due to defective uterine response to implantation . Accordingly, H11 which can omit IL-11Rα and directly achieve gp130 may prove to be beneficial in pregnancy.
We constructed a designer cytokine Hyper IL-11 (H11), which is exclusively composed of naturally existing components. It contains the full length sIL-11Rα linked with the IL-11 using their natural sequences. Accordingly, H11 should not induce of the antibody production and other side effects due to the non-natural recombinant agent. The purified recombinant H11 is a fully active protein. It displayed biological activity in three different in vitro bio-assays: human hepatoma cell line HepG2-assay, B9 and Ba/F3-gp130 proliferation assays. Moreover, it differs in terms of differentiation of hematopoietic cells when compared to the Hyper-IL-6.
Since there are disorders due dysfunction of IL-11 or IL-11Rα, H11 may be potentially applied in the biomedical field. It may be useful for treatment of thrombocytopenia, infertility, multiple sclerosis, cardiovascular diseases or inflammatory disorders. It should be noted however, that due to the fact that Hyper-IL-11 could stimulate all cells in the body, a strategy to properly target the designer cytokine needs to be developed.
Insect cell culture. Sf21 (Spodoptera frugiperda) and High-Five BTI-TN-5B1-4 (Trichoplusia ni) insect cells were routinely cultured at 28°C in ambient CO2 in Grace's Insect Cell Culture Medium supplemented with 10% Fetal Calf Serum (FCS) and Express Five SFM medium, respectively. Monolayer cultures of Sf21 were adapted to suspension growth in Sf-900 II SFM medium on an orbital shaker platform rotating at 150 rpm. For adaptation of High-Five BTI-TN-5B1-4 cells to suspension culture, aggregated cell clamps were allowed to settle for 2 min and then samples for subculturing were taken from the upper layer of the culture. Cells were cultured in 500 ml shake flasks on an orbital shaker platform rotating at 150 rpm. All cell culture media and FCS were of Gibco Invitrogen Corporation (Grand Island, NJ) brand.
Mammalian cell culture. Human hepatoma cells (HepG2) were maintained in DMEM (Gibco Invitrogen, Grand Island, NJ) medium supplemented with 10% FCS. The B9 cell line, a variant of the IL-6 dependent murine hybridoma B13.29, was routinely cultured in DMEM containing 10% FCS and 10% conditioned medium from B78-IL-6 cell line (a source of IL-6)' . The murine bone marrow-derived pro-B-cell line Ba/F3 stably transfected with a gp130 cDNA (Ba/F3-gp130) was maintained in DMEM medium supplemented with 10% FCS and 0.5 ng/ml mIL-3 (Sigma, St. Louis, MO). Lin-CD34+ cells were cultured in serum free X-Vivo10 culture medium (Lonza, Verviers, Belgium). All media contained 80 mg/l gentamycin (KRKA, Novo Mesto, Slowenia) and cell cultures were grown at 37°C in an atmosphere of 95% air-5% CO2.
Construction of hyper IL-11 (H11)
The fragment of human IL-11 cDNA (sequence which corresponds to the amino acid residues 19-199, GenBank:ID: X58377) was amplified by a standard PCR reaction. The amplified fragment of IL-11 was cloned into the pGEM-Teasy vector (Promega, Madison, WI). The cDNA of human IL-11Rα (the amino acid residues 1-365, GenBank:ID: Z388102) was also amplified by PCR. Sequences of the used primers were as follows: IL-11 forward: 5' GCT GCT GCC CCT GGG CCA, IL-11 reverse: 5' TCC GCG GCC GCT ATG GCC GAC GTC GAC TCA CAG CCG AGT CTT CAG, IL-11Rα forward: 5' ACG CGT CGA CGC CAC CAT GGG CAG CAG CTG CTC AGG GCT G, IL-11Rα reverse: 5' AAC TCG AGG GGG GCC AGG TGG TGG CCC AGG GGC GAC AGC CTG CTC CAC AGA GTC CCT. The IL-11Rα PCR product was cloned into the pGEM-Teasy vector and then digested with SalI and XhoI restriction enzymes. The purified fragment SalI/XhoI was cloned into XhoI site of the plasmid pGEM-Teasy/IL-11 leading to the creation of the fused cDNA of IL-11Rα and IL-11 referred as Hyper IL-11 (H11). The sequence has been confirmed by DNA sequencing.
Restriction, DNA modification and amplification enzymes were supplied by Promega (Madison, WI). PCR and plasmid DNA fragments were purified using a QIAquick gel extraction kit (Qiagen, Hilden, Germany) as recommended by the manufacturer. Plasmid DNA was isolated using a QIAprep Spin miniprep Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol.
Production of recombinant H11
For production of recombinant H11 the Bac-To-Bac Baculovirus Expression System was used (Invitrogen Corporation, Carlsbad, CA). First, the pGEM-Teasy/H11 plasmid was digested with SalI/SphI restriction enzymes and the purified cDNA coding for H11 was cloned into the SalI/SphI of pFastBac1 plasmid. The pFastBac1/H11 plasmid was transformed into DH10Bac competent cells, which contain the bacmid with a mini-attTn7 target site and the helper plasmid. The mini-Tn7 element on the pFastBac1 donor plasmid was transposed to the mini-attTn7 target site on the bacmid in the presence of transposition proteins provided by the helper plasmid. The transformed cells were plated on LB-agar plates containing 50 μg/ml kanamycin, 7 μg/ml gentamycin, 10 μg/ml tetracycline, 300 μg/ml Bluo-gal, and 40 μg/ml IPTG. The selected, white colonies were grown in 3 ml clutures overnight and plasmid DNA was isolated. The obtained DNA was analyzed by PCR reaction to confirm the presence of the inserted gene. The following primers were used: Forward #9: 5' ACC CAC CCG CTA CCT CAC CT, Reverse #2: 5' GTC AGG AGC ACG GTG CT.
Propagation the recombinant baculovirus. The Sf21 cells were transfected with recombinant bacmid DNA using Effectene Transfection Reagent (Qiagen, Hilden, Germany) according to the manufacturer's instruction. Shortly, 8 × 105 cells were seeded into Grace's Insect Cell Culture Medium supplemented with 10% FCS in 35 mm well of a 6-well plate and incubated overnight. For transfection-complex formation, 1 μg of bacmid DNA was mixed with 8 μl of Enhancer and 25 μl of Effectene Transfection Reagent. After 10 min incubation, the Grace's Insect Cell Culture Medium supplemented with 10% FCS was added and transferred onto the cells. After 3 days, supernatant was collected and the titer of the virus was assessed using the end-point dilution method according to established procedures . For amplifying viral stocks, 1.4 × 106 of Sf21 cells suspended in Sf-900 II SFM (Gibco Invitrogen, Grand Island, NJ) medium were infected at Multipicity of Infection (MOI) 0.1 for 72 h. The amplifying procedure of the recombinant H11 baculovirus was performed twice and finally the high-quality, high- titer (2.87 × 108 pfu/ml) master virus stock was obtained. The recombinant virus stock was stored at -80°C.
Optimizing of heterologus protein production. In order to achieve an optimal production of recombinant H11 protein, different factors, such as cell lines (Sf21 and High-Five BTI-TN-5B1-4), medium (Sf-900 II SFM and Express Five SFM), parameters of viral infection (MOI) and expression kinetics were considered. To express the recombinant gene product, suspension cultures at a cell density of 1, 1.5, and 2 × 106 cells/ml were infected at MOI 0.5, 1, 5, and 10 pfu/ml and expression of H11 was monitored by dot blot analysis at different harvest times. Optimal production of recombinant H11 protein was achieved at cell density of 1 × 106 cells/ml at MOI 5 for 48 h using High-Five BTI-TN-5B1-4 cells in Express Five SFM medium. Moreover, production of H11 was performed in the presence of Protease Inhibitor Cocktail for use in culture medium (Sigma, St. Louis, MO) at 1:1000 dilution. For dot-blot analysis, hIL-11Rα polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and goat anti rabbit IgG-HRP antibody (DakoCytomation, Glostrup, Denmark) and ECL- kit (Amersham Bioscences, Uppsala, Sweden) were used.
Purification and gel analysis of recombinant H11 protein
Harvested supernatant was diluted with 20 mM 1,3 diaminopropane buffer pH 11.8 at the ratio of 1: 8. Next, the precipitated components were removed by centrifugation at 8 000 g/4°C and batch IEX chromatography was performed overnight at 4°C using Q Sepharose XL anion exchange bed (Amersham Bioscences, Uppsala, Sweden). The Q Sepharose XL was transferred to column and absorbed proteins were eluted using a gradually increasing gradient of salt (0-1 M NaCl) in 20 mM 1,3 diaminopropane buffer pH 10.5. Collected fractions were analyzed by SDS-PAGE gel electrophoresis and Western Blot. Proteins were separated in 10% SDS-PAGE gel and stained with Roti-Blue, Colloidal Coomassie staining (Carl Roth, Karlsruhe, Germany) according to the manufacturer's protocol. For Western blot analysis, the separated proteins were transferred to a PVDF membrane by a semi-dry electroblotting and then blocked in a solution of 10% BSA (Sigma, St. Louis, MO) in TBS-N buffer. For detection of H11, the antibodies and chemiluminescence reagent were used as mentioned before for dot blot analysis. Selected fractions containing recombinant H11 protein were pooled and concentrated by membrane filtration using membranes with a cut-off of 30 kDa (Millipore, Jaffrey, NH). PD-10 Desalting Columns (Amersham Biosciences, Uppsala, Sweden) were used for buffer exchange to PBS and H11 was sterilized by filtration using an Ultrafree-MC sterile 0,22 μm filter unit (Millipore, Jaffrey, NH). The concentration of H11 was estimated by analyzing the band intensities of H11 and serial dilution of BSA of a known concentration using Kodak Molecular Imaging Software v4.5.1.
Stimulation of α1antitrypsin in HepG2 cells by H11
5 × 105 of HepG2 cells were seeded on a 48 well plate and incubated overnight. Next day, cells were washed with serum-free DMEM and then induced with H11 in serum-free medium containing 1 μM dexamethasone. After 48 h supernatants were collected and the amounts of α1 antitrypsin were measured by rocket immunoelectrophoresis using antibody containing 1% agarose gels . The antibody used for this study (Anti-α1-Antitrypsin IgG) was from Sigma (St. Louis, MO). The experiment was repeated three times in duplicate.
The B9 cells (1 × 104 cells/well) were seeded on 96 well plate. Next, the cells were induced with recombinant hIL-11 (Sigma, St. Louis, MO) or H11 at concentrations indicated in Figure 4. The medium without stimulator was used as a negative control. The proliferation of the cells was measured after 72 h using a colorimetric assay based on the MTT reagent (Sigma, St. Louis, MO). For Ba/F3-gp130 studies, 2 × 104 cells per well were seeded on 96 well plates in complete medium and stimulated with increasing concentrations of H11. After 72 h of incubation, proliferation of Ba/F3-gp130 cells was quantified using the MTT reagent. The absorbance of the samples was measured at 562 nm with a microplate reader ELX808IV (Bio-Tek Instruments, Winooski, VT). Each experiment was carried out three times in triplicate.
STAT3 activation in response to hIL-11 and H11
Ba/F3 and Ba/F3-gp130 cells were incubated for 2 h in serum-free medium. Next, 1 × 106 cells were stimulated with hIL-11, H11 or control medium. After 15 min incubation at 37°C, cells were fixed with Fix Buffer I (BD Biosciences Pharmingen, San Jose, CA), washed twice with staining buffer (PBS-0.1%BSA-0.1%NaN3) and permeabilized by adding Perm Buffer III (BD Biosciences Pharmingen, San Jose, CA) and incubating for 30 min on ice. After washing, intracellular staining was performed by adding 5 μl Alexa Fluor 647 labeled anti pSTAT3 antibody (BD Biosciences Pharmingen, San Jose, CA) or Alexa Fluor 647-IgG2a isotype control (BD Biosciences Pharmingen, San Jose, CA). Cells were incubated in the dark for 30 min at room temperature, washed and suspended in 0.5 ml PBS. Analysis of the cells was performed by using a BD Biosciences FACSCANTO flow cytometer and FACSDIVA software. The experiment was repeated three times.
Propagation and differentiation of human Lin-CD34+ cells
Isolation and culture of human Lin-CD34+ cells. Human Lin-CD34+ cells were isolated from fresh cord blood. Light density cells were separated by Ficoll-Hypaque density centrifugation (Sigma, St. Louis, MO). Mature hematopoietic cells such as T cells, B cells, NK cells, dendritic cells, monocytes, granulocytes and erythroid cells were removed by using the Lineage Cell Depletion Kit human (Miltenyi Biotec Inc., Auburn, CA). Resulting Lin-cell fraction was enriched for CD34+ cells by using the CD34 MicroBead Kit human (Miltenyi Biotec Inc., Auburn, CA). Lin-CD34+ cells were cultured in 48-well plates (5 × 104 cells per well) in X-Vivo10 culture medium supplemented with cytokines: cocktail 50 ng/ml rhSCF (PreproTech Inc. Rocky Hill, NJ) and 20 ng/ml rhIL-6 (PreproTech Inc. Rocky Hill, NJ) as control plus 50 ng/ml Hyper-IL6 or 50 ng/ml H11. Hyper-IL-6 was constructed and produced as described previously [14, 31]. Viability and cell number was counted twice weekly. Cells were cultured for two weeks.
Flow cytometric analysis. The differentiation of Lin-CD34+ was evaluated by flow cytometry. Cells were washed twice with PBS and stained for 30 min at 4°C with combinations of the following murine monoclonal antibodies: phycoerythrin (PE)-labeled anti-CD15 (Coulter Beckman, Marseille, France) and phycoerythrin-Cy7 (PE-Cy7)-labelled anti-CD235a (Beckman Coulter, Marseille, France). After labeling procedures, cells were washed once with PBS and analyzed using Coulter Beckman Navios flow cytometer and FlowJo software.
The study was supported by a grants from Ministry of Science and Higher Education, Warsaw, Poland (NN401 1904 33 and NN401 0821 33) and from National Science Centre, Krakow, Poland (2011/01/B/NZ4/05796).
- Du X, Williams DA: Interleukin-11: review of molecular, cell biology, and clinical use. Blood. 1997, 89 (11): 3897-3908.Google Scholar
- Paul SR, Bennett F, Calvetti JA, Kelleher K, Wood CR, O'Hara RM, Leary AC, Sibley B, Clark SC, Williams DA, et al: Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA. 1990, 87 (19): 7512-7516. 10.1073/pnas.87.19.7512.View ArticleGoogle Scholar
- Dams-Kozlowska H, Izycki D, Mackiewicz A: IL-11 is a potent anti-melanoma factor. Adv Exp Med Biol. 2001, 495: 373-377. 10.1007/978-1-4615-0685-0_54.View ArticleGoogle Scholar
- Fasnacht N, Muller W: Conditional gp130 deficient mouse mutants. Semin Cell Dev Biol. 2008, 19 (4): 379-384. 10.1016/j.semcdb.2008.07.001.View ArticleGoogle Scholar
- Jones SA, Scheller J, Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011, 121 (9): 3375-3383. 10.1172/JCI57158.View ArticleGoogle Scholar
- Sims NA, Walsh NC: GP130 cytokines and bone remodelling in health and disease. BMB Rep. 2010, 43 (8): 513-523. 10.5483/BMBRep.2010.43.8.513.View ArticleGoogle Scholar
- Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003, 374 (Pt 1): 1-20.View ArticleGoogle Scholar
- Barton VA, Hall MA, Hudson KR, Heath JK: Interleukin-11 signals through the formation of a hexameric receptor complex. J Biol Chem. 2000, 275 (46): 36197-36203. 10.1074/jbc.M004648200.View ArticleGoogle Scholar
- Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998, 334 (Pt 2): 297-314.View ArticleGoogle Scholar
- Baumann H, Wang Y, Morella KK, Lai CF, Dams H, Hilton DJ, Hawley RG, Mackiewicz A: Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells. J Immunol. 1996, 157 (1): 284-290.Google Scholar
- Curtis DJ, Hilton DJ, Roberts B, Murray L, Nicola N, Begley CG: Recombinant soluble interleukin-11 (IL-11) receptor alpha-chain can act as an IL-11 antagonist. Blood. 1997, 90 (11): 4403-4412.Google Scholar
- Karow J, Hudson KR, Hall MA, Vernallis AB, Taylor JA, Gossler A, Heath JK: Mediation of interleukin-11-dependent biological responses by a soluble form of the interleukin-11 receptor. Biochem J. 1996, 318 (Pt 2): 489-495.View ArticleGoogle Scholar
- Pflanz S, Tacken I, Grotzinger J, Jacques Y, Minvielle S, Dahmen H, Heinrich PC, Muller-Newen G: A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130. FEBS Lett. 1999, 450 (1-2): 117-122. 10.1016/S0014-5793(99)00477-9.View ArticleGoogle Scholar
- Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S: A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol. 1997, 15 (2): 142-145. 10.1038/nbt0297-142.View ArticleGoogle Scholar
- Marz P, Ozbek S, Fischer M, Voltz N, Otten U, Rose-John S: Differential response of neuronal cells to a fusion protein of ciliary neurotrophic factor/soluble CNTF-receptor and leukemia inhibitory factor. Eur J Biochem. 2002, 269 (12): 3023-3031. 10.1046/j.1432-1033.2002.02977.x.View ArticleGoogle Scholar
- Mackiewicz A, Dams-Kozlowska H, Rose-John S: Chimeric soluble Hyper-IL-11 and use thereof. Patent No WO/2005/113591. 2005Google Scholar
- Harrison RL, Jarvis DL: Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce "mammalianized" recombinant glycoproteins. Adv Virus Res. 2006, 68: 159-191.View ArticleGoogle Scholar
- Chow D, He X, Snow AL, Rose-John S, Garcia KC: Structure of an extracellular gp130 cytokine receptor signaling complex. Science. 2001, 291 (5511): 2150-2155. 10.1126/science.1058308.View ArticleGoogle Scholar
- Lu ZY, Zhang XG, Gu ZJ, Yasukawa K, Amiot M, Etrillard M, Bataille R, Klein B: A highly sensitive quantitative bioassay for human interleukin-11. J Immunol Methods. 1994, 173 (1): 19-26. 10.1016/0022-1759(94)90278-X.View ArticleGoogle Scholar
- Schleinkofer K, Dingley A, Tacken I, Federwisch M, Muller-Newen G, Heinrich PC, Vusio P, Jacques Y, Grotzinger J: Identification of the domain in the human interleukin-11 receptor that mediates ligand binding. J Mol Biol. 2001, 306 (2): 263-274. 10.1006/jmbi.2000.4387.View ArticleGoogle Scholar
- Vollmer P, Oppmann B, Voltz N, Fischer M, Rose-John S: A role for the immunoglobulin-like domain of the human IL-6 receptor. Intracellular protein transport and shedding. Eur J Biochem. 1999, 263 (2): 438-446. 10.1046/j.1432-1327.1999.00511.x.View ArticleGoogle Scholar
- Robb L, Hilton DJ, Willson TA, Begley CG: Structural analysis of the gene encoding the murine interleukin-11 receptor alpha-chain and a related locus. J Biol Chem. 1996, 271 (23): 13754-13761. 10.1074/jbc.271.23.13754.View ArticleGoogle Scholar
- Battinelli EM, Hartwig JH, Italiano JE: Delivering new insight into the biology of megakaryopoiesis and thrombopoiesis. Curr Opin Hematol. 2007, 14 (5): 419-426. 10.1097/MOH.0b013e3282bad151.View ArticleGoogle Scholar
- Chevalier S, Fourcin M, Robledo O, Wijdenes J, Pouplard-Barthelaix A, Gascan H: Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. J Biol Chem. 1996, 271 (25): 14764-14772. 10.1074/jbc.271.25.14764.View ArticleGoogle Scholar
- Wijdenes J, Heinrich PC, Muller-Newen G, Roche C, Gu ZJ, Clement C, Klein B: Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur J Immunol. 1995, 25 (12): 3474-3481. 10.1002/eji.1830251240.View ArticleGoogle Scholar
- Gurfein BT, Zhang Y, Lopez CB, Argaw AT, Zameer A, Moran TM, John GR: IL-11 regulates autoimmune demyelination. J Immunol. 2009, 183 (7): 4229-4240. 10.4049/jimmunol.0900622.View ArticleGoogle Scholar
- Robb L, Li R, Hartley L, Nandurkar HH, Koentgen F, Begley CG: Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat Med. 1998, 4 (3): 303-308. 10.1038/nm0398-303.View ArticleGoogle Scholar
- Mackiewicz A, Wiznerowicz M, Roeb E, Karczewska A, Nowak J, Heinrich PC, Rose-John S: Soluble interleukin 6 receptor is biologically active in vivo. Cytokine. 1995, 7 (2): 142-149. 10.1006/cyto.1995.1019.View ArticleGoogle Scholar
- O'Reilly DR, Miller LK, Luckow VA: Baculovirus expression vectors. 1994, Oxford: Oxford University PressGoogle Scholar
- Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S: Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol. 1992, 149 (6): 2021-2027.Google Scholar
- Schroers A, Hecht O, Kallen KJ, Pachta M, Rose-John S, Grotzinger J: Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci. 2005, 14 (3): 783-790. 10.1110/ps.041117105.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.